Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Koopman FJ"'
Autor:
Hilde Rosing, Jan H.M. Schellens, W.W. ten Bokkel Huinink, Mirte M. Malingré, Heleen A. Bardelmeijer, Koopman Fj, Jos H. Beijnen, Margaret Schot, O. van Tellingen, Mariët Ouwehand
Publikováno v:
British Journal of Cancer
The purpose of this study was to investigate the effect of the co-solvents Cremophor EL and polysorbate 80 on the absorption of orally administered paclitaxel. 6 patients received in a randomized setting, one week apart oral paclitaxel 60 mg m−2 di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::365fe26f965ec5f5a55ae27e8f97737f
https://doi.org/10.1054/bjoc.2001.2118
https://doi.org/10.1054/bjoc.2001.2118
Publikováno v:
Journal of Liquid Chromatography & Related Technologies. 24:2697-2717
The taxanes paclitaxel and docetaxel are important anticancer agents. To optimize therapy of these drugs, many studies have been performed by us with pharmacokinetic monitoring of the compounds. The numerous determinations of paclitaxel and docetaxel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df7a8fb7010d0a5be7c14841e3af6c9e
https://doi.org/10.1081/jlc-100106096
https://doi.org/10.1081/jlc-100106096
Autor:
Mirte M. Malingré, Ken Duchin, Olaf van Tellingen, Koopman Fj, M. Swart, Jan Lieverst, Jan H.M. Schellens, Hilde Rosing, Wim W. ten Bokkel Huinink, Jos H. Beijnen
Publikováno v:
Cancer Chemotherapy and Pharmacology. 47:347-354
Purpose: To investigate dose escalation of bi-daily (b.i.d.) oral paclitaxel in combination with cyclosporin A in order to improve and prolong the systemic exposure to paclitaxel and to explore the maximum tolerated dose and dose limiting toxicity (D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c9aac7dc46d183777e7159aed0b47ab
https://doi.org/10.1007/s002800000226
https://doi.org/10.1007/s002800000226
Autor:
Koopman Fj, Margaret Schot, Hilde Rosing, Dick J. Richel, Jan H.M. Schellens, Wim W. ten Bokkel Huinink, Jos H. Beijnen, Mirte M. Malingré
Publikováno v:
Journal of Clinical Oncology. 19:1160-1166
PURPOSE: Oral bioavailability of docetaxel is very low, which is, at least in part, due to its affinity for the intestinal drug efflux pump P-glycoprotein (P-gp). In addition, metabolism of docetaxel by cytochrome P450 (CYP) 3A4 in gut and liver may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f807c970d11d16b4cab003d96cee6618
https://doi.org/10.1200/jco.2001.19.4.1160
https://doi.org/10.1200/jco.2001.19.4.1160
Autor:
Mirte M. Malingré, Hilde Rosing, Koopman Fj, Jos H. Beijnen, Jan H.M. Schellens, Elaine M. Paul, W.W. ten Bokkel Huinink, R. C. Jewell
Publikováno v:
British Journal of Cancer
Oral bioavailability of paclitaxel is very low, which is due to efficient transport of the drug by the intestinal drug efflux pump P-glycoprotein (P-gp). We have recently demonstrated that the oral bioavailability of paclitaxel can be increased at le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9f9f1a6d638f3526cd8f22a458118f4
https://doi.org/10.1054/bjoc.2000.1543
https://doi.org/10.1054/bjoc.2000.1543
Autor:
Koopman Fj, M. Swart, Duchin K, Mirte M. Malingré, Jos H. Beijnen, Jan H.M. Schellens, Huinink Ww, van Tellingen O, Hilde Rosing
Publikováno v:
Anti-Cancer Drugs. 11:813-820
The objective of this study was to compare the quantitative excretion of paclitaxel and metabolites after i.v. and oral drug administration. Four patients received 300 mg/m2 paclitaxel orally 30 min after 15 mg/kg oral cyclosporin A, co-administered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0590d0303f1c5ac117678ba892ca68ed
https://doi.org/10.1097/00001813-200011000-00004
https://doi.org/10.1097/00001813-200011000-00004
Autor:
D Fraier, Koopman Fj, E. Frigerio, J. M. Meerum Terwogt, Jan H.M. Schellens, Hilde Rosing, M. Rocchetti, W.W. ten Bokkel Huinink, Jos H. Beijnen
Publikováno v:
Journal of Liquid Chromatography & Related Technologies. 23:1233-1251
A high-performance liquid chromatographic (HPLC) assay has been designed for the quantitative determination of polymer-bound paclitaxel (after hydrolytic release of paclitaxel from the polymer) and free paclitaxel in human plasma after intravenous ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c3e7929535ee264b964e37892013c9f
https://doi.org/10.1081/jlc-100100411
https://doi.org/10.1081/jlc-100100411
Autor:
Margaret Schot, Maria G Zurlo, I.A.M. Mandjes, Marurizio Rocchetti, Jan H.M. Schellens, Hilde Rosing, Koopman Fj, Wim W. ten Bokkel Huinink, Jetske M. Meerum Terwogt, Jos H. Beijnen
Publikováno v:
Anti-cancer drugs. 12(4)
Intravenous administration of paclitaxel is hindered by poor water solubility of the drug. Currently, paclitaxel is dissolved in a mixture of ethanol and Cremophor EL; however, this formulation (Taxol) is associated with significant side effects, whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5666adfbecafb9c0ecc2ad26caee7852
https://pubmed.ncbi.nlm.nih.gov/11335787
https://pubmed.ncbi.nlm.nih.gov/11335787
Autor:
Mirte M. Malingré, Hilde Rosing, M. Swart, Duchin K, Koopman Fj, Jan Lieverst, van Tellingen O, ten Bokkel Huinink Ww, Jan H.M. Schellens, Jos H. Beijnen
Publikováno v:
Anti-cancer drugs. 12(4)
The objective of this study was to define the minimally effective dose of cyclosporin A (CsA) that would result in a maximal increase of the systemic exposure to oral paclitaxel. Six evaluable patients participated in this randomized cross-over study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ad20ca0684428f778d7b11846c5ea5
https://pubmed.ncbi.nlm.nih.gov/11335792
https://pubmed.ncbi.nlm.nih.gov/11335792
Autor:
Jan H.M. Schellens, van Tellingen O, Michel J.X. Hillebrand, Koopman Fj, R. Dubbelman, Jos H. Beijnen, Hilde Rosing, Vinodh R. Nannan Panday, ten Bokkel Huinink Ww
Publikováno v:
Anti-cancer drugs. 9(8)
Doxorubicin and paclitaxel both display strong antitumor activity in the treatment of breast cancer. The optimal schedule of this combination, however, remains undefined. In this phase I and pharmacologic study, we administered weekly 12 mg/m2 doxoru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd91a870114bf4edc66cd8fe3edfed1b
https://pubmed.ncbi.nlm.nih.gov/9823424
https://pubmed.ncbi.nlm.nih.gov/9823424